BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 9815806)

  • 21. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
    Curtis KK; Hartney JT; Jewell RC; Park JW; Lebowitz PF; Griffin PP; Borad MJ; Fitch TR; Northfelt DW
    J Clin Pharmacol; 2010 Mar; 50(3):268-75. PubMed ID: 19808951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
    Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Hütter G; Szélenyi H; Deckert PM; Keilholz U; Thiel E
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):178-84. PubMed ID: 15114411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.